Agna Bailey, DO
Family Medicine · Willow Park, TXNPI 1598762825
Payments from drug & device makers
Across 193 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$534
- AbbVie$366
- Boehringer Ingelheim$349
- Novo Nordisk$253
- Sanofi-aventis U.S. LLC$246
- Lilly USA, LLC$179
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,219100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $534 |
| AbbVie(2 entities) | 32 | $366 |
| Boehringer Ingelheim | 16 | $349 |
| Novo Nordisk | 18 | $253 |
| Sanofi-aventis U.S. LLC | 8 | $246 |
| Lilly USA, LLC | 12 | $179 |
| Amgen | 13 | $179 |
| Pfizer | 9 | $127 |
| Motiva USA, LLC | 1 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $78 |
| GSK | 5 | $73 |
| Astellas Pharma US Inc | 4 | $58 |
| Exact Sciences | 3 | $57 |
| Abbott | 3 | $54 |
| Merck | 3 | $47 |
| Upsher-smith Laboratories LLC | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Amarin Pharma, Inc. | 2 | $32 |
| Biogen | 1 | $30 |
| Shire North American Group Inc | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 6 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Insulet Corporation | 1 | $23 |
| IBSA Pharma Inc. | 1 | $21 |
| Eisai Inc. | 1 | $17 |
| Avvisto Therapeutics, LLC | 1 | $16 |
| Si-bone, Inc. | 1 | $16 |
| MDD US Operations, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
| Tanabe Pharma America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$158
- BREZTRI$158
- AIRSUPRA$158
- SOLIQUA 100/33$123
- Motiva Implant Matrix$120
How this compares
$3,225 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $135,814 |
| EliquisApixaban | 96 | $95,000 |
| JardianceEmpagliflozin | 78 | $91,558 |
| JanuviaSitagliptin Phosphate | 29 | $34,738 |
| TrulicityDulaglutide | 16 | $32,686 |
| MyrbetriqMirabegron | 23 | $19,934 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $18,472 |
| MounjaroTirzepatide | 11 | $18,390 |
| FarxigaDapagliflozin Propanediol | 11 | $15,280 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $14,338 |
| VascepaIcosapent Ethyl | 23 | $11,247 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $10,081 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $9,516 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $7,418 |
| Levothyroxine Sodium | 671 | $6,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $253 | $135,814102 claims |
| PfizerEliquis | $127 | $95,00096 claims |
| Boehringer IngelheimJardiance | $349 | $91,55878 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $179 | $51,07627 claims |
| MerckJanuvia, Janumet | $47 | $49,07648 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $73 | $24,54338 claims |
| AstraZenecaFarxiga, Symbicort | $534 | $20,23228 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $19,93423 claims |
| AbbVieSynthroid | $366 | $3,17783 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Willow Park
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.